Senseonics Holdings, Inc. (SENS)
| Market Cap | 257.53M |
| Revenue (ttm) | 23.30M |
| Net Income (ttm) | -80.59M |
| Shares Out | 530.89M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | 21.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,383,103 |
| Open | 0.495 |
| Previous Close | 0.492 |
| Day's Range | 0.481 - 0.504 |
| 52-Week Range | 0.384 - 1.050 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 1.25 (+157.68%) |
| Earnings Date | May 13, 2024 |
About SENS
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare provider... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SENS stock is "Buy." The 12-month stock price forecast is $1.25, which is an increase of 157.68% from the latest price.
News
Senseonics Holdings, Inc. Reports First Quarter 2024 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics and Mercy Collaborate to Improve Diabetes Population Health Management
GERMANTOWN, Md. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantab...
Senseonics Partners with Rimidi to Develop Innovative Diabetes Solution
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Participate in Upcoming Conferences
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 13, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Eversense® CGM System Receives iCGM Designation by the US FDA
GERMANTOWN, Md. & PARSIPPANY, N.J.--(BUSINESS WIRE)--Eversense® CGM System Receives iCGM Designation by the US FDA.
SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS
Eligible individuals in the U.S. will pay $99 out of pocket for each 6-month CGM system, offering each year of continuous glucose monitoring for just $200* PARSIPPANY, N.J. , March 12, 2024 /PRNewswir...
Senseonics Holdings, Inc. Announces Data From the Eversense® Post Approval Study to Be Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Participate in the Oppenheimer 34th Annual Healthcare MedTech and Services Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for February 29, 2024 at 4:30 P.M. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Medicare Coverage Significantly Expanded for the Eversense E3 CGM System
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development ...
MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM
The decision is further recognition of Eversense as an important option for people with diabetes PARSIPPANY, N.J. , Feb. 12, 2024 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company...
PHC Holdings Corporation and Senseonics Announce Appointment of Brian Hansen as President of CGM at Ascensia Diabetes Care
TOKYO--(BUSINESS WIRE)--PHC Holdings Corporation (TSE: 6523) (hereafter PHCHD), the parent company of Ascensia Diabetes Care, a global diabetes care company, along with Senseonics Holdings, Inc. (NYSE...
Senseonics Holdings, Inc. Announces Business Updates
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life' Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes
PARSIPPANY, N.J. & GERMANTOWN, Md.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused o...
Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...
Senseonics Announces Equity Grants To Employees Under Inducement Plan
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucos...